Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Most relevant
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
End-of-day quote. End-of-day quote Japan Exchange - 12/07
1781 JPY   +0.91%
12/06ASTELLAS PHARMA : New Research Organization Structure
PU
12/06ASTELLAS PHARMA : Presentation Material for R&D Meeting
PU
12/06ASTELLAS PHARMA : Corporate Governance Report
PU
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ASTELLAS PHARMA INC.
05:46aAstellas Applied for Selection of 'Prime Market' segment of the Tokyo Stock Exchange
AQ
12/06ASTELLAS PHARMA : New Research Organization Structure
PU
12/06ASTELLAS PHARMA : Presentation Material for R&D Meeting
PU
12/06ASTELLAS PHARMA : Corporate Governance Report
PU
12/06ASTELLAS PHARMA : Applied for Selection of “Prime Market”segment of the Tokyo ..
PU
12/06ASTELLAS PHARMA : Applied for Selection of “Prime Market” segment of the Tokyo..
PU
12/05ASTELLAS PHARMA : Corporate Covernance Report
PU
12/02Astellas to Present Research on FLT3 Mutation, Positive Acute Myeloid Leukemia from Dia..
AQ
12/02Japanese shares end lower on Omicron worries, Fed's hawkish tilt
RE
12/01Japanese shares fall on Omicron, Fed worries
RE
12/01ASTELLAS PHARMA : to Present Research on FLT3 Mutation-Positive Acute Myeloid Leukemia &nd..
PU
11/30ASTELLAS PHARMA : Patient centricity at Astellas—all about action
PU
11/30WE PUBLISHED A STORY : “Patient centricity at Astellas—all about action.&rdquo..
PU
11/26ASTELLAS PHARMA : Annual Report 2021 is now available.
PU
11/25ASTELLAS PHARMA : Pivotal Phase 3 Trial for Pediatric Praziquantel Completes with Positive..
PU
11/19ASTELLAS PHARMA : ' Efforts Against the Spread of the Coronavirus Disease (COVID-19)
PU
11/14ASTELLAS PHARMA : and Pantherna Enter into Technology Evaluation Agreement for Research of..
PU
11/12PLAUSIBILITY AND UNDUE BURDEN : A New Look Insufficiency After FibroGen v Akebia
AQ
11/02Earnings call script
PU
10/28Financial Results (Q2/FY2021)
PU
10/28Supplementary Documents (Q2/FY2021)
PU
10/28Presentation Material for Information Meeting (Q2/FY2021)
PU
10/28Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Full Year Ending Ma..
CI
10/25ASTELLAS PHARMA : We published our corporate brand movie on the VISION section.
PU
10/19ASTELLAS PHARMA : Receives “2021 Award for Excellence in Corporate Disclosure”..
PU
10/13Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfo..
AQ
10/12ASTELLAS PHARMA : and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV..
PU
10/12SEAGEN : Astellas Complete Enrollment in Cohort K of Study of Padcev, Keytruda Combination..
MT
10/12ASTELLAS PHARMA : Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combini..
BU
10/11ASTELLAS PHARMA : World's First Use of Environmentally Friendly Biomass-based Plastic for ..
PU
10/01ASTELLAS PHARMA : Juntendo University and Astellas Establish "Direct Reprogramming Regener..
PU
09/30ASTELLAS PHARMA : Corporate Strategic Plan 2021—dedicated to realization
PU
09/30ASTELLAS PHARMA : announces the publication of New Contents related to its Corporate Strat..
PU
09/29ASTELLAS PHARMA : Recognized Consistently Among Top Companies for Working Parents
AQ
09/29ASTELLAS PHARMA INC. : Ex-dividend day for interim dividend
FA
09/28ASTELLAS PHARMA : Japan's MHLW Approves PADCEV (enfortumab vedotin) for Advanced Urothelia..
AQ
09/27SEAGEN : Urothelial Cancer Drug Padcev Gets Japanese Regulator's Approval
MT
09/27ASTELLAS PHARMA : Japan's MHLW Approves PADCEV (enfortumab vedotin) for Advanced Urothelia..
PU
09/27ASTELLAS PHARMA : Japan's MHLW Approves PADCEV« (enfortumab vedotin) for Advanced Urotheli..
BU
09/23ASTELLAS PHARMA : Tohoku University and Astellas Establish Second Phase of Comprehensive I..
PU
09/23ASTELLAS PHARMA INC. : will present 12-week results (S-13) from the pivotal Phase 3 SKYLIG..
AQ
09/22Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic..
AQ
09/22Astellas to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2Ö Trial in Ora..
CI
09/22ASTELLAS PHARMA : to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2™ ..
PU
09/21ASTELLAS PHARMA : Science-based Exercise at Home with Fit-eNce HomeTM Pilot Sales Begins T..
PU
09/20ASTELLAS PHARMA : ' and Pfizer's XTANDI« (enzalutamide) Reduced Risk of Death by 34% in Me..
PU
09/20ASTELLAS PHARMA : ' and pfizer's xtandi (enzalutamide) reduced risk of death by 34% in men..
AQ
09/09ASTELLAS PHARMA : Updates “Contact for Potential Acquisition of ' R&D Programs&rdquo..
PU
09/02ASTELLAS PHARMA : Nitto, and M. Heart Partnering for ECG testing service
PU
09/01Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked My..
CI
08/31ASTELLAS PHARMA : Announces Personnel Changes
PU
08/30ASTELLAS PHARMA : Launches its Corporate Website's New Modalities~Approach for Cell..
PU
08/20SECTOR UPDATE : Health Care Stocks Mixed Premarket Friday
MT
08/20FIBROGEN : Receives $120 Million Milestone Payment With Approval of Evrenzo in Europe
MT
08/20ASTELLAS PHARMA : Receives European Commission Approval for First-in-Class EVRENZOTM (roxa..
PU
08/19ASTELLAS PHARMA : Receives European Commission Approval for First-in-Class EVRENZO™á..
AQ
08/19ASTELLAS PHARMA : Receives EC Approval for First-inClass EVRENZO (roxadustat) for Adult Pa..
PU
08/19Astellas Receives EC Approval for First-Inclass Evrenzo for Adult Patients with Symptom..
CI
08/18Nikkei snaps 4-day losing streak, but Delta worries persist
RE
08/17Japanese shares bounce back as defensive stocks gain
RE
08/11FDA Rejects FibroGen's Roxadustat for Anemia of Chronic Kidney Disease
DJ
08/06ASTELLAS PHARMA : Reforms Research Organization
PU
08/05Modalis Announces Completion of a Research Collaboration on Angelman Syndrome and Regai..
CI
07/30ASTELLAS PHARMA : and Minovia Therapeutics Announce Strategic Collaboration for Novel Mito..
BU
07/30Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondr..
CI
07/30Astellas Pharma Inc. Revises Earnings Guidance for the Full Year 2022
CI
07/30Astellas Pharma Inc. Reports Earnings Results for the First Quarter Ended June 30, 2021
CI
07/29ASTELLAS PHARMA : Financial Results (Q1/FY2021)
PU
07/29ASTELLAS PHARMA : Presentation Material for Information Meeting (Q1/FY2021)
PU
07/29ASTELLAS PHARMA : Supplementary Documents (Q1/FY2021)
PU
07/20The U.S. Food and Drug Administration Approves Astellas Pharma Inc.'s Supplemental New ..
CI
07/13ExCellThera and Astellas Enters into a License for the Use of Molecule UM171 in the Fie..
CI
07/12Affinivax and Astellas Presents Safety and Immunogenicity Data from Phase 2 Study of AS..
CI
07/12ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PADCEV (enfo..
AQ
07/11ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PADCEV(enfor..
PU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on ASTELLAS PHARMA INC.
12/07/21